정밀 종양학 시장 규모, 점유율, 동향 분석 보고서 : 제품 유형별, 암 종류별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Precision Oncology Market Size, Share & Trends Analysis Report By Product Type (Diagnostics, Therapeutics), By Cancer Type (Breast Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer), By End-use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,530,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,964,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,831,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

정밀 종양학 시장 성장과 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 정밀 종양학 시장 규모는 2030년까지 2,019억 6,000만 달러에 달할 것으로 예상되며, 2025년부터 2030년까지 연평균 8.05%의 CAGR을 기록할 것으로 예상됩니다.

정밀 종양학은 종양 분자 프로파일링에 중점을 둔 성장 분야로, 시장 제품들이 유전자 변화를 확인하기 위해 종양의 분자 프로파일링에 초점을 맞추고 있습니다. 현재 이 분야는 95%의 환자 반응률과 함께 질적으로 조정된 생존기간의 연장으로 큰 성공을 거두고 있습니다. 시장 제품은 병원과 클리닉에서 환자 치료의 개선과 더 나은 정보에 입각한 의사결정의 가능성을 제공합니다. 또한, 전 세계적으로 암의 유병률 증가, 임상시험 연구의 증가, 정밀 종양 진단 기술의 급속한 채택은 시장 수요를 증가시킬 것으로 예상됩니다.

COVID-19 사태로 인해 전 세계적으로 암환자에 대한 의료가 확대되고, 암환자 치료의 범위가 넓어지면서 정밀 종양학 시장도 큰 영향을 받았습니다. 또한, 정밀 종양학을 이용한 진단과 치료의 지연은 암 환자의 진단과 치료에 큰 영향을 미쳤습니다. 그러나 COVID-19 사태 이후 정밀 종양학은 더 나은 치료 결과를 제공하고 암 환자의 삶의 질을 향상시키기 때문에 시장은 급속한 수요를 얻고 있습니다.

2022년 1월, OnXerna Therapeutics, Inc.와 Exact Sciences Corp.는 미국에서 OnXerna의 TME Panel 실험실 서비스를 환자에게 도입하기로 합의했다고 발표했습니다. TME Panel은 혁신적인 유전자 발현 점수이며, 면역요법 및 항혈관 신생 요법에 반응하는 환자를 식별하는 데 도움이 될 수 있습니다. 또한, 회사는 바이오파마 파트너를 통해 임상의에게 Xerna TME Panel을 동반진단약물로서, 그리고 기존 정밀 종양학 팀으로서 임상의에게 Xerna TME Panel에 대한 접근성을 제공할 것이라고 덧붙였습니다.

정밀 종양학 시장 보고서 하이라이트

• 제품 유형별로는 특정 유전자 변이에 대한 표적 치료제의 개발 및 승인 증가로 인해 치료제 분야가 2024년 71.3%의 최대 매출 점유율을 기록하며 시장을 주도했습니다.
• 암 유형별로는 유방암 분야가 2024년 41.7%의 최대 매출 점유율로 시장을 주도했습니다.
• 최종 용도별로는 병원 및 진단 분야가 2024년 46.8%의 최대 매출 점유율로 시장을 주도했습니다. 병원 및 진단 분야에서 정밀 종양학 제품은 유전자 변화를 확인하기 위한 종양의 분자 프로파일링에 중점을 두고 있어 전 세계적으로 관심이 높아지고 있습니다.
• 북미 정밀 종양학 시장은 2024년 44.0%의 가장 큰 매출 점유율을 차지했습니다. 이 시장의 우위는 개인화된 치료 접근법을 가능하게 하는 첨단 진단 도구의 가용성이 증가하고 있기 때문입니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 정밀 종양학 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 견인 요인 분석
  • 시장 성장 억제요인 분석
• 정밀 종양학 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 정밀 종양학 시장 : 제품 유형 추정·동향 분석

• 제품 유형 시장 점유율, 2024년 및 2030년
• 부문 대시보드
• 제품 유형별 세계 정밀 종양학 시장 전망
• 2018년부터 2030년까지 시장 규모와 예측 및 동향 분석
  • 진단
  • 치료

제5장 정밀 종양학 시장 : 암 종류 추정·동향 분석

• 암 종류별 시장 점유율, 2024년 및 2030년
• 부문 대시보드
• 암 종류별 세계 정밀 종양학 시장 전망
• 2018년부터 2030년까지 시장 규모와 예측 및 동향 분석
  • 유방암
  • 대장암
  • 자궁경부암
  • 전립선암
  • 폐암
  • 기타

제6장 정밀 종양학 시장 : 최종 용도 추정·동향 분석

• 최종 용도 시장 점유율, 2024년 및 2030년
• 부문 대시보드
• 최종 용도별 세계 정밀 종양학 시장 전망
• 2018년부터 2030년까지 시장 규모와 예측 및 동향 분석
  • 병원과 진단
  • 제약 및 바이오테크놀러지
  • 헬스케어 데이터 기업

제7장 정밀 종양학 시장 : 지역 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년 및 2030년
• 지역 시장 대시보드
• 세계 지역 시장 현황
• 시장 규모와 예측 동향 분석, 2018년에서 2030년 :
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제8장 경쟁 구도

• 주요 시장 진출 기업의 최근 동향과 영향 분석
• 기업/경쟁 분류
• 벤더 상황
  • Key company market share analysis, 2024
  • Thermo Fisher Scientific Inc.
  • Invitae Corporation
  • Qiagen NV
  • Illumina, Inc.
  • Laboratory Corporation of America Holding
  • Exact Sciences Corporation
  • Rain Oncology Inc.
  • Strata Oncology Inc.
  • Xilis, Inc.
  • Variantyx, Inc.
  • Bioserve
  • Relay Therapeutics
  • Acrivon Therapeutics

ksm

영문 목차

영문목차

Precision Oncology Market Growth & Trends:

The global precision oncology market size is expected to reach USD 201.96 billion by 2030, registering a CAGR of 8.05% from 2025 to 2030, according to a new report by Grand View Research, Inc. Precision oncology is a growing field where the market products emphasize on molecular profiling of tumors to identify alterations in the gene. Currently, the industry has witnessed major success with a 95% response rate being observed in patients along with extended quality-adjusted life. The market products offer the potential for improved patient care and a better-informed decision-making experience in hospitals and clinics. Alternatively, the increasing prevalence of cancer across the globe, the rising number of clinical trial studies, and the rapid adoption of technology in precision oncology diagnostic is anticipated to boost the market demand.

Due to the COVID-19 pandemic, the precision oncology market had a huge impact as the pandemic exaggerated healthcare across the globe for people living with cancer, possessing a unique set of challenges. Besides, delayed diagnosis and therapeutics using precision oncology have affected cancer patient diagnosis and treatment to a major extent. However, post-COVID-19 pandemic, the market has gained rapid demand as precision oncology offers better therapeutic outcomes and improves the quality of patient life for cancer patients.

In January 2022, OncXerna Therapeutics, Inc. and Exact Sciences Corp. mentioned the agreement to introduce OncXerna's TME Panel lab services for patients in the U.S. It is an innovative gene expression score, which helps identify patients to respond to immunotherapies and anti-angiogenic. Further, the company added that it believes to provide clinician access to the Xerna TME Panel through biopharma partners as a companion diagnostic and existing precision oncology team.

Precision Oncology Market Report Highlights:

• Based on product type, the therapeutics segment led the market with the largest revenue share of 71.3% in 2024, due to the increasing development and approval of targeted treatments tailored to specific genetic mutations.
• Based on cancer type, the breast cancer segment led the market with the largest revenue share of 41.7% in 2024, attributed to increasing awareness for breast cancer screening, diagnosis, and surgical and radiation techniques.
• Based on end-use, the hospitals and diagnostic segment led the market with the largest revenue share of 46.8% in 2024. In hospital and diagnostic, precision oncology products are garnering an increasing amount of interest worldwide as it emphases molecular profiling of tumors to identify alterations in the gene.
• North America precision oncology market dominated with the largest revenue share of 44.0% in 2024. The market dominance can be attributed to the increasing availability of advanced diagnostic tools that enable personalized treatment approaches.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product Type
  • 1.2.2. Cancer Type
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product type outlook
  • 2.2.2. Cancer type outlook
  • 2.2.3. End Use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Precision Oncology Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising Prevalence of Cancer
    • 3.2.1.2. Advancements in Genomics and Molecular Diagnostics:
    • 3.2.1.3. Supportive Government and Private Sector Initiatives
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Costs of Precision Oncology Therapies
    • 3.2.2.2. Limited Access to Advanced Diagnostic Technologies:
• 3.3. Precision Oncology Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Precision Oncology Market: Product Type Estimates & Trend Analysis

• 4.1. Product Type Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Precision Oncology Market by Product Type Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Diagnostics
    • 4.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.2. Therapeutics
    • 4.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Precision Oncology Market: Cancer Type Estimates & Trend Analysis

• 5.1. Cancer Type Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Precision Oncology Market by Cancer Type Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Breast Cancer
    • 5.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.2. Colorectal Cancer
    • 5.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.3. Cervical Cancer
    • 5.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.4. Prostate Cancer
    • 5.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.5. Lung Cancer
    • 5.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.6. Others
    • 5.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Precision Oncology Market: End Use Estimates & Trend Analysis

• 6.1. End Use Market Share, 2024 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Precision Oncology Market by End Use Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Hospitals and Diagnostic
    • 6.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4.2. Pharmaceutical and Biotechnology
    • 6.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4.3. Healthcare Data Companies
    • 6.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Precision Oncology Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Target disease prevalence
    • 7.5.1.5. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Target disease prevalence
    • 7.5.2.5. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Target disease prevalence
    • 7.5.3.5. Mexico market estimates and forecasts, 2018 to 2030, (USD Million
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Target disease prevalence
    • 7.6.1.5. UK market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Target disease prevalence
    • 7.6.2.5. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. Target disease prevalence
    • 7.6.3.5. France market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Target disease prevalence
    • 7.6.4.5. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Target disease prevalence
    • 7.6.5.5. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Target disease prevalence
    • 7.6.6.5. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/ reimbursement structure
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Target disease prevalence
    • 7.6.7.5. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/ reimbursement structure
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Target disease prevalence
    • 7.6.8.5. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Target disease prevalence
    • 7.7.1.5. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Target disease prevalence
    • 7.7.2.5. China market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. Target disease prevalence
    • 7.7.3.5. India market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Target disease prevalence
    • 7.7.4.5. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. Target disease prevalence
    • 7.7.5.5. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/ reimbursement structure
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Target disease prevalence
    • 7.7.6.5. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Target disease prevalence
    • 7.8.1.5. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Target disease prevalence
    • 7.8.2.5. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework/ reimbursement structure
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. Target disease prevalence
    • 7.9.1.5. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/ reimbursement structure
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Target disease prevalence
    • 7.9.2.5. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/ reimbursement structure
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. Target disease prevalence
    • 7.9.3.5. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/ reimbursement structure
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Target disease prevalence
    • 7.9.4.5. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key company market share analysis, 2024
  • 8.3.2. Thermo Fisher Scientific Inc.
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Product benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Invitae Corporation
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Product benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. Qiagen N.V.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Illumina, Inc.
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Laboratory Corporation of America Holding
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Exact Sciences Corporation
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Rain Oncology Inc.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Strata Oncology Inc.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Xilis, Inc.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Variantyx, Inc.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Bioserve
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Relay Therapeutics
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. Acrivon Therapeutics
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Product benchmarking
    • 8.3.14.4. Strategic initiatives

관련자료